
The funding will be for a GLP-1 receptor agonist clinical programme for weight loss

Results show trevogrumab prevents lean mass and muscle loss during GLP-1 weight loss

NSV is a chronic autoimmune disease where the immune system attacks melanin-producing cells, leading to a loss of pigment

There are currently no approved human vaccines for Lyme disease

Litfulo delivered significant, clinically meaningful improvements for both face and body

The phase 3 trial showed greater than 50% improvement in radiographic progression-free survival

Patients who had received only one prior line of systemic therapy showed a stronger trend for overall survival and progression-free survival

The companies plan to research and develop 12 new cancer treatments

The companies aim to develop next-generation oral medicines for obesity and diabetes

Almost three billion people globally are thought to be either overweight or obese

Obesity affects approximately 15 million people in the UK

Colorectal cancer is the third most common cancer globally, with approximately 1.8 million people diagnosed in 2022